Lintuzumab-Ac225
Showing 1 - 25 of 362
Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- (no location specified)
Feb 22, 2022
Refractory Multiple Myeloma Trial in United States (Lintuzumab AC 225)
Terminated
- Refractory Multiple Myeloma
- Lintuzumab AC 225
-
Los Angeles, California
- +4 more
Feb 22, 2022
Acute Myeloid Leukemia, Relapsed Adult AML Trial in United States (Lintuzumab-Ac225, Venetoclax, Spironolactone)
Recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
-
Los Angeles, California
- +4 more
Feb 22, 2022
AML Trial in Puerto Rico, United States (Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only))
Completed
- AML
- Cytarabine (Phase 1 only)
- +3 more
-
Los Angeles, California
- +16 more
Feb 22, 2022
Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 225Ac-PSMA-R2
- 68Ga-PSMA-R2
- (no location specified)
Aug 8, 2023
Uveal Melanoma, Metastatic Trial in Tampa (4.7 microCi 225Ac-MTI-201, 9.5 microCi of 225Ac-MTI-201, 19 microCi of 225Ac-MTI-201)
Recruiting
- Uveal Melanoma
- Metastatic
- 4.7 microCi 225Ac-MTI-201
- +11 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 9, 2022
Prostatic Tumors, Castration-Resistant Trial in Rotterdam (Radionuclide Therapy)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- Radionuclide Therapy
-
Rotterdam, Zuid-Holland, NetherlandsErasmus Medical Center
Jun 5, 2023
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- FPI-2053
- +2 more
-
Irvine, California
- +2 more
Nov 27, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Actinium Ac 225-DOTA-Daratumumab
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- 225^Ac-PSMA-617
- 68^Ga-PSMA-11
-
Darlinghurst, Australia
- +1 more
Nov 23, 2022
Prostate Cancer Trial in New Orleans, New York (225Ac-J591)
Active, not recruiting
- Prostate Cancer
-
New Orleans, Louisiana
- +1 more
Nov 15, 2022
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer Trial in Omaha
Recruiting
- Pancreatic Ductal Adenocarcinoma (PDAC)
- +6 more
-
Omaha, NebraskaUrology Cancer Center/XCancer
Nov 29, 2022
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Metastatic Castration Resistant Prostate Cancer Trial in Houston (Ac225-PSMA I&T)
Recruiting
- Metastatic Castration Resistant Prostate Cancer
- Ac225-PSMA I&T
-
Houston, TexasExcel Diagnostics and Nuclear Oncology Center
Jan 27, 2022
Advanced Solid Tumours, Actinium-225, Antineoplastic Agents Trial in Australia, Canada, United States ([111In]-FPI-1547
Recruiting
- Advanced Solid Tumours
- +4 more
- [111In]-FPI-1547 Injection
- +3 more
-
Duarte, California
- +12 more
Mar 2, 2022
Prostate Cancer Trial in Glen Burnie, Omaha, Knoxville (PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122)
Recruiting
- Prostate Cancer
- PSMA-Targeted [In-111]-Labeled Trillium Compound
- PTI-122
-
Glen Burnie, Maryland
- +2 more
Mar 21, 2023
Prostate Cancer Trial in Brooklyn, New York (225Ac-J591, 68Ga-PSMA-HBED-CC injection)
Recruiting
- Prostate Cancer
- 225Ac-J591
- 68Ga-PSMA-HBED-CC injection
-
Brooklyn, New York
- +1 more
Nov 23, 2020
Metastatic Castration-resistant Prostate Cancer Trial (225Ac-PSMA)
Unknown status
- Metastatic Castration-resistant Prostate Cancer
- (no location specified)
Jan 8, 2020
Metastatic Castration-resistant Prostate Cancer Trial in Finland, Netherlands, United Kingdom (BAY3546828, BAY2616505,
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- BAY3546828
- +2 more
-
Helsinki, Finland
- +3 more
Sep 18, 2023
Long COVID Trial in Sheffield (Probiotic, Placebo)
Recruiting
- Long COVID
- Probiotic
- Placebo
-
Sheffield, United KingdomSheffield Hallam University
Aug 2, 2023
SCLC,Extensive Stage Trial in Omaha (RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3)
Recruiting
- SCLC,Extensive Stage
- RYZ101 Dose Level 1
- +6 more
-
Omaha, NebraskaNebraska Cancer Specialists
Nov 18, 2022